Claims for Patent: 6,046,202

Summary for Patent: 6,046,202

Title:	Use of thiazolidinedione derivatives in the treatment of insulin resistance
Abstract:	The present invention provides methods of using thiazolidinedione in the treatment of insulin resistance.
Inventor(s):	Antonucci; Tammy (Thousand Oaks, CA), Lockwood; Dean (Ann Arbor, MI), Norris; Rebecca (Kewadin, MI)
Assignee:	Warner-Lambert Company (Morris Plains, NJ)
Application Number:	09/168,515
Patent Claims:	1. A method of treating a patient having insulin resistance characterized by hyperinsulinemia and failure to respond to exogenous insulin, the method comprising administering to the patient a therapeutically effective amount of (+)-5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl )methoxy]phenyl]methyl]-2,4-thiazolidinedione (Troglitazone). 2. A method of treating a patient having insulin resistance characterized by hyperinsulinemia and failure to respond to exogenous insulin, the method comprising administering to the patient a therapeutically effective amount of 5-[p-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione (Pioglitazone). 3. A method of treating a patient having insulin resistance characterized by hyperinsulinemia and failure to respond to exogenous insulin, the method comprising administering to the patient a therapeutically effective amount of 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione (Rosiglitazone).